Befloxatone

This classification denotes a monoamine oxidase inhibitor with the molecular formula C15H18F3NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4H75PAD8M3, chemically known as 2-oxazolidinone, 5-(methoxymethyl)-3-(4-(4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-, (r,(r*,r*))- but generally known as befloxatone, which bears US NIH Compound Identifier 60824. European Medicines Agency schedules Befloxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05681MIG. The term BEFLOXATONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). BEFLOXATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule befloxatone under HS 29349990 and SITC 51579. As of Q4 2014, BEFLOXATONE remains the US FDA Preferred Term for this commodity. Befloxatone bears US NLM identifiers UMLS ID C0289919 and NCI Concept Code C77519. SMILES: FC(F)(F)C(O)CCOc1ccc(N2CC(OC2=O)COC)cc1.